NCT05940116View on ClinicalTrials.gov

A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

322

Participants

Timeline

Start Date

July 20, 2023

Primary Completion Date

July 30, 2025

Study Completion Date

July 30, 2027

Conditions

Non-Small Cell Lung CancerSolid Tumor

Interventions

DRUG

HS-20117

"Phase Ia: patients will receive HS-20117 starting at 400 mg, and subsequent cohorts will test escalating doses, if tolerated, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined.~Phase Ib: patients will receive HS-20117 at MED or MAD"

Trial Locations (1)

300181

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors

lead

Hansoh BioMedical R&D Company

INDUSTRY

NCT05940116 - A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter